Summary in two lines. > Pfizer said the vaccine missed the trial’s statistical goal because not enough people in the study contracted Lyme disease to be confid

Summary in two lines. > Pfizer said the vaccine missed the trial’s statistical goal because not enough people in the study contracted Lyme disease to be confident in the results. > Still, the company said the shot reduced the rate of infection by more than 70% in people who received the vaccine versus placebo It doesn't sound like it "failed the trial" for bad reasons, just an unfortunate one. Hopefully progress can be made, however since it is already treatable with antibiotics we probably shouldn't look to fast track this.